Wealthspire Advisors LLC Buys 174 Shares of Stryker Co. (NYSE:SYK)

Wealthspire Advisors LLC grew its stake in Stryker Co. (NYSE:SYK) by 2.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,099 shares of the medical technology company’s stock after purchasing an additional 174 shares during the period. Wealthspire Advisors LLC’s holdings in Stryker were worth $2,126,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Farmers & Merchants Trust Co of Chambersburg PA raised its stake in shares of Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 61 shares during the period. Rogco LP bought a new stake in Stryker in the fourth quarter worth about $30,000. HBC Financial Services PLLC purchased a new position in shares of Stryker during the fourth quarter valued at approximately $37,000. Bourgeon Capital Management LLC bought a new position in shares of Stryker during the fourth quarter valued at approximately $37,000. Finally, Operose Advisors LLC raised its holdings in shares of Stryker by 308.6% in the third quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after buying an additional 108 shares during the period. Institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a research report on Wednesday, May 1st. Truist Financial upped their target price on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research note on Wednesday, January 31st. TD Cowen increased their price objective on Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Barclays upped their target price on Stryker from $372.00 to $376.00 and gave the stock an “overweight” rating in a report on Thursday, May 2nd. Finally, BTIG Research upped their price target on shares of Stryker from $366.00 to $369.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $365.94.

Stryker Price Performance

Shares of Stryker stock traded up $1.58 on Thursday, reaching $330.86. The company’s stock had a trading volume of 980,396 shares, compared to its average volume of 1,327,501. The company has a quick ratio of 0.99, a current ratio of 1.71 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $126.04 billion, a P/E ratio of 37.77, a PEG ratio of 2.54 and a beta of 0.91. The stock has a 50-day moving average price of $345.60 and a 200-day moving average price of $318.91. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping analysts’ consensus estimates of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The company had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. During the same period in the prior year, the business posted $2.14 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. Analysts expect that Stryker Co. will post 11.94 EPS for the current year.

Insider Buying and Selling

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.